-$0.16 Earnings Per Share Expected for Abeona Therapeutics Inc (ABEO) This Quarter

Equities research analysts expect Abeona Therapeutics Inc (NASDAQ:ABEO) to post earnings of ($0.16) per share for the current quarter, Zacks reports. Four analysts have made estimates for Abeona Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.05) and the lowest estimate coming in at ($0.20). Abeona Therapeutics reported earnings of ($0.21) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 23.8%. The business is expected to announce its next earnings results on Tuesday, August 21st.

According to Zacks, analysts expect that Abeona Therapeutics will report full-year earnings of ($0.70) per share for the current financial year, with EPS estimates ranging from ($0.89) to ($0.34). For the next financial year, analysts forecast that the firm will report earnings of ($0.64) per share, with EPS estimates ranging from ($0.98) to ($0.29). Zacks’ earnings per share calculations are an average based on a survey of analysts that follow Abeona Therapeutics.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings data on Monday, May 14th. The biopharmaceutical company reported ($0.18) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.01. Abeona Therapeutics had a negative return on equity of 23.57% and a negative net margin of 939.83%. The business had revenue of $2.60 million during the quarter, compared to the consensus estimate of $0.27 million.



ABEO has been the subject of several recent analyst reports. HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Abeona Therapeutics in a research note on Friday, April 20th. Cantor Fitzgerald restated a “buy” rating and set a $36.00 target price on shares of Abeona Therapeutics in a research note on Wednesday, May 16th. SunTrust Banks decreased their target price on Abeona Therapeutics to $23.00 and set a “positive” rating for the company in a research note on Wednesday, May 16th. BidaskClub upgraded Abeona Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, April 14th. Finally, Maxim Group set a $35.00 target price on Abeona Therapeutics and gave the stock a “buy” rating in a research note on Monday, May 14th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $28.56.

Hedge funds and other institutional investors have recently modified their holdings of the business. Bank of New York Mellon Corp lifted its stake in Abeona Therapeutics by 89.8% in the fourth quarter. Bank of New York Mellon Corp now owns 195,474 shares of the biopharmaceutical company’s stock valued at $3,097,000 after buying an additional 92,465 shares during the last quarter. Virtus Fund Advisers LLC purchased a new stake in Abeona Therapeutics in the fourth quarter valued at approximately $346,000. EAM Investors LLC lifted its stake in Abeona Therapeutics by 50.3% in the fourth quarter. EAM Investors LLC now owns 221,175 shares of the biopharmaceutical company’s stock valued at $3,506,000 after buying an additional 74,002 shares during the last quarter. Teacher Retirement System of Texas purchased a new stake in Abeona Therapeutics in the fourth quarter valued at approximately $163,000. Finally, Virtu Financial LLC purchased a new stake in Abeona Therapeutics in the fourth quarter valued at approximately $246,000. Institutional investors own 69.11% of the company’s stock.

Shares of Abeona Therapeutics stock traded down $0.20 on Friday, reaching $15.90. 850,422 shares of the company were exchanged, compared to its average volume of 1,082,414. Abeona Therapeutics has a 1-year low of $4.55 and a 1-year high of $22.75. The company has a market cap of $749.79 million, a PE ratio of -23.94 and a beta of 1.27.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Get a free copy of the Zacks research report on Abeona Therapeutics (ABEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply